Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, Ph.D., will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 2:45 PM ET. The presentation aims to update on the company’s progress in developing small molecule, tumor-agnostic therapies for genetically defined cancers. A live webcast will be available on their investor relations website, with a replay accessible for three weeks. Black Diamond employs a proprietary MAP platform to target undrugged mutations in cancer.

CAMBRIDGE, Mass. and NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Morgan Stanley 18^th Annual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 2:45 PM ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com

FAQ

When will Black Diamond Therapeutics present at the Morgan Stanley Global Healthcare Conference?

Black Diamond Therapeutics will present on September 15, 2020, at 2:45 PM ET.

How can I access the Black Diamond Therapeutics presentation?

The presentation can be accessed via a live webcast on the investor relations section of their website.

What is the focus of Black Diamond Therapeutics’ research?

The company focuses on developing small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.

What is the MAP platform used by Black Diamond Therapeutics?

The MAP platform is a proprietary technology designed to identify oncogenic mutations and develop targeted therapies for cancer.

How long will the replay of Black Diamond Therapeutics’ presentation be available?

The replay will be available and archived on their website for three weeks following the presentation.